Phaseline

Companies › RANI Therapeutics

RANI Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PG-102
Tumor necrosis factor receptor superfamily member 5 inhibitor
CD40Phase 1Obesity; Type 2 Diabetes Mellitus (T2DM)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06712615PG-102Phase 2Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineOct 2025
NCT06891287PG-102Phase 1ObesityMetabolic and endocrineDec 2026

From the company's SEC filings

Cash of $4m on 2026-09-30; operating cash outflow about $31m a year; runway about 1 months at that burn, to Nov 2026

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD40 (1)

Companies with the same targets

AbbVie Xencor Genmab Roche Akamis Bio Alligator Bioscience Veloxis Pharmaceuticals Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.